We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Pharmacokinetic and safety data from healthy volunteers anticipated in the second half of 2025 On track to initiate a proof-of-concept study in psoriasis in the second half of 2025, with initial...
MENLO PARK, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a biotechnology company developing novel biologics designed to set a new standard for the...
MENLO PARK, Calif., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a biotechnology company developing novel biologics designed to set a new standard for the...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -1 | -4.54545454545 | 22 | 23.57 | 19.8375 | 990605 | 21.04076086 | CS |
4 | 0.29 | 1.40028971511 | 20.71 | 25.65 | 18.2 | 389922 | 21.28079014 | CS |
12 | -1.8 | -7.89473684211 | 22.8 | 31.13 | 18.2 | 220969 | 23.16488337 | CS |
26 | -4.5 | -17.6470588235 | 25.5 | 31.13 | 18.2 | 180639 | 23.28930473 | CS |
52 | -4.5 | -17.6470588235 | 25.5 | 31.13 | 18.2 | 180639 | 23.28930473 | CS |
156 | -4.5 | -17.6470588235 | 25.5 | 31.13 | 18.2 | 180639 | 23.28930473 | CS |
260 | -4.5 | -17.6470588235 | 25.5 | 31.13 | 18.2 | 180639 | 23.28930473 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions